#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Tailoring Immunotherapy in Real-Life Clinical Practice
1-1	0-2	3.	_	_	_	_
1-2	3-12	Tailoring	_	_	_	_
1-3	13-26	Immunotherapy	abstract	new	coref	2-20[11_0]
1-4	27-29	in	_	_	_	_
1-5	30-39	Real-Life	abstract[2]	new[2]	coref	5-15[45_2]
1-6	40-48	Clinical	abstract[2]	new[2]	_	_
1-7	49-57	Practice	abstract[2]	new[2]	_	_

#Text=After the histology-agnostic approval of pembrolizumab in mismatch repair ( MMR)-deficient tumors , the predictive molecular pathology scenario in cancer immunotherapy changed radically .
2-1	58-63	After	_	_	_	_
2-2	64-67	the	event[3]	new[3]	_	_
2-3	68-86	histology-agnostic	event[3]	new[3]	_	_
2-4	87-95	approval	event[3]	new[3]	_	_
2-5	96-98	of	event[3]	new[3]	_	_
2-6	99-112	pembrolizumab	event[3]|substance[4]	new[3]|new[4]	_	_
2-7	113-115	in	event[3]|substance[4]	new[3]|new[4]	_	_
2-8	116-124	mismatch	event[3]|substance[4]|object|abstract[6]|object[7]	new[3]|new[4]|new|new[6]|new[7]	coref	10-6[64_7]
2-9	125-131	repair	event[3]|substance[4]|abstract[6]|object[7]	new[3]|new[4]|new[6]|new[7]	_	_
2-10	132-133	(	event[3]|substance[4]|object[7]	new[3]|new[4]|new[7]	_	_
2-11	134-148	MMR)-deficient	event[3]|substance[4]|object[7]	new[3]|new[4]|new[7]	_	_
2-12	149-155	tumors	event[3]|substance[4]|object[7]	new[3]|new[4]|new[7]	_	_
2-13	156-157	,	_	_	_	_
2-14	158-161	the	abstract[9]	new[9]	_	_
2-15	162-172	predictive	abstract[9]	new[9]	_	_
2-16	173-182	molecular	abstract[9]	new[9]	_	_
2-17	183-192	pathology	abstract|abstract[9]	new|new[9]	_	_
2-18	193-201	scenario	abstract[9]	new[9]	_	_
2-19	202-204	in	abstract[9]	new[9]	_	_
2-20	205-211	cancer	abstract[9]|abstract|abstract[11]	new[9]|new|giv[11]	coref	4-11[25_11]
2-21	212-225	immunotherapy	abstract[9]|abstract[11]	new[9]|giv[11]	_	_
2-22	226-233	changed	_	_	_	_
2-23	234-243	radically	_	_	_	_
2-24	244-245	.	_	_	_	_

#Text=For the first time in the history of medicine , a drug ( in this case , an immune-checkpoint inhibitor ) was approved based on a specific molecular feature of the neoplasm , irrespective of its anatomical site of origin .
3-1	246-249	For	_	_	_	_
3-2	250-253	the	time[12]	new[12]	coref	14-33[99_12]
3-3	254-259	first	time[12]	new[12]	_	_
3-4	260-264	time	time[12]	new[12]	_	_
3-5	265-267	in	time[12]	new[12]	_	_
3-6	268-271	the	time[12]|abstract[13]	new[12]|new[13]	_	_
3-7	272-279	history	time[12]|abstract[13]	new[12]|new[13]	_	_
3-8	280-282	of	time[12]|abstract[13]	new[12]|new[13]	_	_
3-9	283-291	medicine	time[12]|abstract[13]|abstract	new[12]|new[13]|new	_	_
3-10	292-293	,	_	_	_	_
3-11	294-295	a	substance[15]	new[15]	coref	19-20[135_15]
3-12	296-300	drug	substance[15]	new[15]	_	_
3-13	301-302	(	_	_	_	_
3-14	303-305	in	_	_	_	_
3-15	306-310	this	abstract[16]|abstract[17]	new[16]|new[17]	_	_
3-16	311-315	case	abstract[16]|abstract[17]	new[16]|new[17]	_	_
3-17	316-317	,	abstract[17]	new[17]	_	_
3-18	318-320	an	abstract[17]	new[17]	_	_
3-19	321-338	immune-checkpoint	abstract[17]	new[17]	_	_
3-20	339-348	inhibitor	abstract[17]	new[17]	_	_
3-21	349-350	)	_	_	_	_
3-22	351-354	was	_	_	_	_
3-23	355-363	approved	_	_	_	_
3-24	364-369	based	_	_	_	_
3-25	370-372	on	_	_	_	_
3-26	373-374	a	abstract[18]	new[18]	_	_
3-27	375-383	specific	abstract[18]	new[18]	_	_
3-28	384-393	molecular	abstract[18]	new[18]	_	_
3-29	394-401	feature	abstract[18]	new[18]	_	_
3-30	402-404	of	abstract[18]	new[18]	_	_
3-31	405-408	the	abstract[18]|substance[19]	new[18]|new[19]	ana	3-36[0_19]
3-32	409-417	neoplasm	abstract[18]|substance[19]	new[18]|new[19]	_	_
3-33	418-419	,	_	_	_	_
3-34	420-432	irrespective	_	_	_	_
3-35	433-435	of	_	_	_	_
3-36	436-439	its	substance|place[21]	giv|new[21]	_	_
3-37	440-450	anatomical	place[21]	new[21]	_	_
3-38	451-455	site	place[21]	new[21]	_	_
3-39	456-458	of	place[21]	new[21]	_	_
3-40	459-465	origin	place[21]|abstract	new[21]|new	_	_
3-41	466-467	.	_	_	_	_

#Text=A multitude of different tools has been proposed to inform immunotherapy , including morphology , immunohistochemistry ( IHC ) , polymerase chain reaction ( PCR)-based techniques and next-generation technology assays , such as next-generation sequencing ( NGS ) or multiplex barcode technology ( e.g. , NanoString ) .
4-1	468-469	A	abstract[23]	new[23]	_	_
4-2	470-479	multitude	abstract[23]	new[23]	_	_
4-3	480-482	of	abstract[23]	new[23]	_	_
4-4	483-492	different	abstract[23]|abstract[24]	new[23]|new[24]	coref	5-4[42_24]
4-5	493-498	tools	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-6	499-502	has	_	_	_	_
4-7	503-507	been	_	_	_	_
4-8	508-516	proposed	_	_	_	_
4-9	517-519	to	_	_	_	_
4-10	520-526	inform	_	_	_	_
4-11	527-540	immunotherapy	abstract[25]	giv[25]	coref	8-8[0_25]
4-12	541-542	,	abstract[25]	giv[25]	_	_
4-13	543-552	including	abstract[25]	giv[25]	_	_
4-14	553-563	morphology	abstract[25]|abstract	giv[25]|new	_	_
4-15	564-565	,	abstract[25]	giv[25]	_	_
4-16	566-586	immunohistochemistry	abstract[25]|abstract	giv[25]|new	appos	4-18
4-17	587-588	(	abstract[25]	giv[25]	_	_
4-18	589-592	IHC	abstract[25]|abstract	giv[25]|giv	coref	17-4[117_0]
4-19	593-594	)	abstract[25]	giv[25]	_	_
4-20	595-596	,	abstract[25]	giv[25]	_	_
4-21	597-607	polymerase	abstract[25]|substance|event[31]|abstract[32]	giv[25]|new|new[31]|new[32]	coref	22-11[144_32]
4-22	608-613	chain	abstract[25]|abstract|event[31]|abstract[32]	giv[25]|new|new[31]|new[32]	_	_
4-23	614-622	reaction	abstract[25]|event[31]|abstract[32]	giv[25]|new[31]|new[32]	_	_
4-24	623-624	(	abstract[25]|abstract[32]	giv[25]|new[32]	_	_
4-25	625-635	PCR)-based	abstract[25]|abstract[32]	giv[25]|new[32]	_	_
4-26	636-646	techniques	abstract[25]|abstract[32]	giv[25]|new[32]	_	_
4-27	647-650	and	abstract[25]	giv[25]	_	_
4-28	651-666	next-generation	abstract[25]|abstract[33]|abstract[34]	giv[25]|new[33]|new[34]	coref	19-3[130_34]
4-29	667-677	technology	abstract[25]|abstract[33]|abstract[34]	giv[25]|new[33]|new[34]	_	_
4-30	678-684	assays	abstract[25]|abstract[34]	giv[25]|new[34]	_	_
4-31	685-686	,	abstract[25]|abstract[34]	giv[25]|new[34]	_	_
4-32	687-691	such	abstract[25]|abstract[34]	giv[25]|new[34]	_	_
4-33	692-694	as	abstract[25]|abstract[34]	giv[25]|new[34]	_	_
4-34	695-710	next-generation	abstract[25]|abstract[34]|abstract|abstract[36]	giv[25]|new[34]|new|new[36]	appos	4-37[0_36]
4-35	711-721	sequencing	abstract[25]|abstract[34]|abstract[36]	giv[25]|new[34]|new[36]	_	_
4-36	722-723	(	_	_	_	_
4-37	724-727	NGS	abstract	giv	coref	11-23
4-38	728-729	)	_	_	_	_
4-39	730-732	or	_	_	_	_
4-40	733-742	multiplex	place|abstract[40]	new|new[40]	appos	4-44[41_40]
4-41	743-750	barcode	abstract|abstract[40]	new|new[40]	_	_
4-42	751-761	technology	abstract[40]	new[40]	_	_
4-43	762-763	(	_	_	_	_
4-44	764-768	e.g.	abstract[41]	giv[41]	_	_
4-45	769-770	,	abstract[41]	giv[41]	_	_
4-46	771-781	NanoString	abstract[41]	giv[41]	_	_
4-47	782-783	)	_	_	_	_
4-48	784-785	.	_	_	_	_

#Text=However , not all the available tools are validated for patients ’ selection in clinical practice , as shown in
5-1	786-793	However	_	_	_	_
5-2	794-795	,	_	_	_	_
5-3	796-799	not	_	_	_	_
5-4	800-803	all	abstract[42]	giv[42]	_	_
5-5	804-807	the	abstract[42]	giv[42]	_	_
5-6	808-817	available	abstract[42]	giv[42]	_	_
5-7	818-823	tools	abstract[42]	giv[42]	_	_
5-8	824-827	are	_	_	_	_
5-9	828-837	validated	_	_	_	_
5-10	838-841	for	_	_	_	_
5-11	842-850	patients	person[43]|abstract[44]	new[43]|new[44]	coref|coref	8-6[0_43]|23-6[150_44]
5-12	851-852	’	person[43]|abstract[44]	new[43]|new[44]	_	_
5-13	853-862	selection	abstract[44]	new[44]	_	_
5-14	863-865	in	_	_	_	_
5-15	866-874	clinical	abstract[45]	giv[45]	coref	25-7[168_45]
5-16	875-883	practice	abstract[45]	giv[45]	_	_
5-17	884-885	,	_	_	_	_
5-18	886-888	as	_	_	_	_
5-19	889-894	shown	_	_	_	_
5-20	895-897	in	_	_	_	_

#Text=Figure 1
6-1	898-904	Figure	abstract[46]	new[46]	_	_
6-2	905-906	1	abstract[46]	new[46]	_	_

#Text=.
7-1	907-908	.	_	_	_	_

#Text=Among new biomarkers to select patients for immunotherapy , the tumor mutational burden ( TMB ) has been shown a strong correlation with the response to some compounds .
8-1	909-914	Among	_	_	_	_
8-2	915-918	new	abstract[47]	new[47]	_	_
8-3	919-929	biomarkers	abstract[47]	new[47]	_	_
8-4	930-932	to	abstract[47]	new[47]	_	_
8-5	933-939	select	abstract[47]	new[47]	_	_
8-6	940-948	patients	abstract[47]|person	new[47]|giv	_	_
8-7	949-952	for	abstract[47]	new[47]	_	_
8-8	953-966	immunotherapy	abstract[47]|abstract	new[47]|giv	coref	23-11
8-9	967-968	,	_	_	_	_
8-10	969-972	the	abstract[52]	new[52]	appos	8-15[0_52]
8-11	973-978	tumor	object|abstract[52]	new|new[52]	coref	9-17
8-12	979-989	mutational	abstract|abstract[52]	new|new[52]	_	_
8-13	990-996	burden	abstract[52]	new[52]	_	_
8-14	997-998	(	_	_	_	_
8-15	999-1002	TMB	abstract	giv	coref	9-1
8-16	1003-1004	)	_	_	_	_
8-17	1005-1008	has	_	_	_	_
8-18	1009-1013	been	_	_	_	_
8-19	1014-1019	shown	_	_	_	_
8-20	1020-1021	a	abstract[54]	new[54]	_	_
8-21	1022-1028	strong	abstract[54]	new[54]	_	_
8-22	1029-1040	correlation	abstract[54]	new[54]	_	_
8-23	1041-1045	with	abstract[54]	new[54]	_	_
8-24	1046-1049	the	abstract[54]|abstract[55]	new[54]|new[55]	coref	10-20[67_55]
8-25	1050-1058	response	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-26	1059-1061	to	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-27	1062-1066	some	abstract[54]|abstract[55]|substance[56]	new[54]|new[55]|new[56]	_	_
8-28	1067-1076	compounds	abstract[54]|abstract[55]|substance[56]	new[54]|new[55]|new[56]	_	_
8-29	1077-1078	.	_	_	_	_

#Text=TMB is defined by the total number of somatic nonsynonymous mutations per coding area of the tumor DNA .
9-1	1079-1082	TMB	abstract	giv	coref	10-8[65_0]
9-2	1083-1085	is	_	_	_	_
9-3	1086-1093	defined	_	_	_	_
9-4	1094-1096	by	_	_	_	_
9-5	1097-1100	the	abstract[58]	new[58]	_	_
9-6	1101-1106	total	abstract[58]	new[58]	_	_
9-7	1107-1113	number	abstract[58]	new[58]	_	_
9-8	1114-1116	of	abstract[58]	new[58]	_	_
9-9	1117-1124	somatic	abstract[58]|abstract[59]	new[58]|new[59]	_	_
9-10	1125-1138	nonsynonymous	abstract[58]|abstract[59]	new[58]|new[59]	_	_
9-11	1139-1148	mutations	abstract[58]|abstract[59]	new[58]|new[59]	_	_
9-12	1149-1152	per	abstract[58]|abstract[59]	new[58]|new[59]	_	_
9-13	1153-1159	coding	abstract[58]|abstract[59]|abstract[60]	new[58]|new[59]|new[60]	_	_
9-14	1160-1164	area	abstract[58]|abstract[59]|abstract[60]	new[58]|new[59]|new[60]	_	_
9-15	1165-1167	of	abstract[58]|abstract[59]|abstract[60]	new[58]|new[59]|new[60]	_	_
9-16	1168-1171	the	abstract[58]|abstract[59]|abstract[60]|abstract[62]	new[58]|new[59]|new[60]|new[62]	ana	10-1[0_62]
9-17	1172-1177	tumor	abstract[58]|abstract[59]|abstract[60]|object|abstract[62]	new[58]|new[59]|new[60]|giv|new[62]	coref	14-23
9-18	1178-1181	DNA	abstract[58]|abstract[59]|abstract[60]|abstract[62]	new[58]|new[59]|new[60]|new[62]	_	_
9-19	1182-1183	.	_	_	_	_

#Text=It has been hypothesized that tumors with a higher TMB are more likely to express neoantigens and to induce a more robust immune response in the presence of immune checkpoint inhibitors .
10-1	1184-1186	It	abstract	giv	_	_
10-2	1187-1190	has	_	_	_	_
10-3	1191-1195	been	_	_	_	_
10-4	1196-1208	hypothesized	_	_	_	_
10-5	1209-1213	that	_	_	_	_
10-6	1214-1220	tumors	object[64]	giv[64]	coref	18-4[121_64]
10-7	1221-1225	with	object[64]	giv[64]	_	_
10-8	1226-1227	a	object[64]|abstract[65]	giv[64]|giv[65]	coref	11-4[0_65]
10-9	1228-1234	higher	object[64]|abstract[65]	giv[64]|giv[65]	_	_
10-10	1235-1238	TMB	object[64]|abstract[65]	giv[64]|giv[65]	_	_
10-11	1239-1242	are	_	_	_	_
10-12	1243-1247	more	_	_	_	_
10-13	1248-1254	likely	_	_	_	_
10-14	1255-1257	to	_	_	_	_
10-15	1258-1265	express	_	_	_	_
10-16	1266-1277	neoantigens	abstract	new	_	_
10-17	1278-1281	and	_	_	_	_
10-18	1282-1284	to	_	_	_	_
10-19	1285-1291	induce	_	_	_	_
10-20	1292-1293	a	abstract[67]	giv[67]	ana	12-19[0_67]
10-21	1294-1298	more	abstract[67]	giv[67]	_	_
10-22	1299-1305	robust	abstract[67]	giv[67]	_	_
10-23	1306-1312	immune	abstract[67]	giv[67]	_	_
10-24	1313-1321	response	abstract[67]	giv[67]	_	_
10-25	1322-1324	in	_	_	_	_
10-26	1325-1328	the	abstract[68]	new[68]	_	_
10-27	1329-1337	presence	abstract[68]	new[68]	_	_
10-28	1338-1340	of	abstract[68]	new[68]	_	_
10-29	1341-1347	immune	abstract[68]|place[69]|abstract[70]	new[68]|new[69]|new[70]	_	_
10-30	1348-1358	checkpoint	abstract[68]|place[69]|abstract[70]	new[68]|new[69]|new[70]	_	_
10-31	1359-1369	inhibitors	abstract[68]|abstract[70]	new[68]|new[70]	_	_
10-32	1370-1371	.	_	_	_	_

#Text=Regrettably , the TMB analysis is considered expensive , time-consuming , and deceptive if the analyses are carried out with an unsuitable NGS panel .
11-1	1372-1383	Regrettably	_	_	_	_
11-2	1384-1385	,	_	_	_	_
11-3	1386-1389	the	abstract[72]	new[72]	coref	12-5[78_72]
11-4	1390-1393	TMB	abstract|abstract[72]	giv|new[72]	coref	12-5
11-5	1394-1402	analysis	abstract[72]	new[72]	_	_
11-6	1403-1405	is	_	_	_	_
11-7	1406-1416	considered	_	_	_	_
11-8	1417-1426	expensive	_	_	_	_
11-9	1427-1428	,	_	_	_	_
11-10	1429-1443	time-consuming	_	_	_	_
11-11	1444-1445	,	_	_	_	_
11-12	1446-1449	and	_	_	_	_
11-13	1450-1459	deceptive	_	_	_	_
11-14	1460-1462	if	_	_	_	_
11-15	1463-1466	the	abstract[73]	new[73]	coref	18-20[126_73]
11-16	1467-1475	analyses	abstract[73]	new[73]	_	_
11-17	1476-1479	are	_	_	_	_
11-18	1480-1487	carried	_	_	_	_
11-19	1488-1491	out	_	_	_	_
11-20	1492-1496	with	_	_	_	_
11-21	1497-1499	an	object[75]	new[75]	_	_
11-22	1500-1510	unsuitable	object[75]	new[75]	_	_
11-23	1511-1514	NGS	abstract|object[75]	giv|new[75]	_	_
11-24	1515-1520	panel	object[75]	new[75]	_	_
11-25	1521-1522	.	_	_	_	_

#Text=Another important facet in TMB analysis is represented by the lack of widely adopted guidelines and recommendations for its assessment and reporting .
12-1	1523-1530	Another	abstract[76]	new[76]	_	_
12-2	1531-1540	important	abstract[76]	new[76]	_	_
12-3	1541-1546	facet	abstract[76]	new[76]	_	_
12-4	1547-1549	in	abstract[76]	new[76]	_	_
12-5	1550-1553	TMB	abstract[76]|abstract|abstract[78]	new[76]|giv|giv[78]	coref|ana	13-3|14-17[0_78]
12-6	1554-1562	analysis	abstract[76]|abstract[78]	new[76]|giv[78]	_	_
12-7	1563-1565	is	_	_	_	_
12-8	1566-1577	represented	_	_	_	_
12-9	1578-1580	by	_	_	_	_
12-10	1581-1584	the	abstract[79]	new[79]	_	_
12-11	1585-1589	lack	abstract[79]	new[79]	_	_
12-12	1590-1592	of	abstract[79]	new[79]	_	_
12-13	1593-1599	widely	abstract[79]|abstract[80]	new[79]|new[80]	coref	22-17[0_80]
12-14	1600-1607	adopted	abstract[79]|abstract[80]	new[79]|new[80]	_	_
12-15	1608-1618	guidelines	abstract[79]|abstract[80]	new[79]|new[80]	_	_
12-16	1619-1622	and	abstract[79]	new[79]	_	_
12-17	1623-1638	recommendations	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-18	1639-1642	for	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-19	1643-1646	its	abstract[79]|abstract[81]|abstract|abstract[83]	new[79]|new[81]|giv|new[83]	coref	30-13[211_0]
12-20	1647-1657	assessment	abstract[79]|abstract[81]|abstract[83]	new[79]|new[81]|new[83]	_	_
12-21	1658-1661	and	abstract[79]|abstract[81]	new[79]|new[81]	_	_
12-22	1662-1671	reporting	abstract[79]|abstract[81]|abstract	new[79]|new[81]|new	_	_
12-23	1672-1673	.	_	_	_	_

#Text=Initially , TMB was determined using wide approaches ( e.g. , whole exome sequencing ) , but more focused gene panels are currently being explored .
13-1	1674-1683	Initially	_	_	_	_
13-2	1684-1685	,	_	_	_	_
13-3	1686-1689	TMB	abstract	giv	coref	14-9
13-4	1690-1693	was	_	_	_	_
13-5	1694-1704	determined	_	_	_	_
13-6	1705-1710	using	_	_	_	_
13-7	1711-1715	wide	abstract[86]	new[86]	appos	13-10[88_86]
13-8	1716-1726	approaches	abstract[86]	new[86]	_	_
13-9	1727-1728	(	_	_	_	_
13-10	1729-1733	e.g.	abstract[88]	giv[88]	_	_
13-11	1734-1735	,	abstract[88]	giv[88]	_	_
13-12	1736-1741	whole	abstract[88]	giv[88]	_	_
13-13	1742-1747	exome	abstract|abstract[88]	new|giv[88]	_	_
13-14	1748-1758	sequencing	abstract[88]	giv[88]	_	_
13-15	1759-1760	)	_	_	_	_
13-16	1761-1762	,	_	_	_	_
13-17	1763-1766	but	_	_	_	_
13-18	1767-1771	more	abstract[90]	new[90]	coref	15-7[104_90]
13-19	1772-1779	focused	abstract[90]	new[90]	_	_
13-20	1780-1784	gene	abstract|abstract[90]	new|new[90]	_	_
13-21	1785-1791	panels	abstract[90]	new[90]	_	_
13-22	1792-1795	are	_	_	_	_
13-23	1796-1805	currently	_	_	_	_
13-24	1806-1811	being	_	_	_	_
13-25	1812-1820	explored	_	_	_	_
13-26	1821-1822	.	_	_	_	_

#Text=In addition , there are several indications that TMB is not a universal biomarker , as its value varies not only across tumor types but also across different genomic regions and during the time .
14-1	1823-1825	In	_	_	_	_
14-2	1826-1834	addition	_	_	_	_
14-3	1835-1836	,	_	_	_	_
14-4	1837-1842	there	_	_	_	_
14-5	1843-1846	are	_	_	_	_
14-6	1847-1854	several	abstract[91]	new[91]	_	_
14-7	1855-1866	indications	abstract[91]	new[91]	_	_
14-8	1867-1871	that	abstract[91]	new[91]	_	_
14-9	1872-1875	TMB	abstract[91]|abstract|abstract[93]	new[91]|giv|new[93]	coref	15-8
14-10	1876-1878	is	abstract[91]|abstract[93]	new[91]|new[93]	_	_
14-11	1879-1882	not	abstract[91]|abstract[93]	new[91]|new[93]	_	_
14-12	1883-1884	a	abstract[91]|abstract[93]	new[91]|new[93]	_	_
14-13	1885-1894	universal	abstract[91]|abstract[93]	new[91]|new[93]	_	_
14-14	1895-1904	biomarker	abstract[91]|abstract[93]	new[91]|new[93]	_	_
14-15	1905-1906	,	_	_	_	_
14-16	1907-1909	as	_	_	_	_
14-17	1910-1913	its	abstract|abstract[95]	giv|new[95]	coref|coref	16-3[107_0]|29-7[204_95]
14-18	1914-1919	value	abstract[95]	new[95]	_	_
14-19	1920-1926	varies	_	_	_	_
14-20	1927-1930	not	_	_	_	_
14-21	1931-1935	only	_	_	_	_
14-22	1936-1942	across	_	_	_	_
14-23	1943-1948	tumor	object|abstract[97]	giv|new[97]	coref|coref	20-16|20-15[142_97]
14-24	1949-1954	types	abstract[97]	new[97]	_	_
14-25	1955-1958	but	_	_	_	_
14-26	1959-1963	also	_	_	_	_
14-27	1964-1970	across	_	_	_	_
14-28	1971-1980	different	place[98]	new[98]	_	_
14-29	1981-1988	genomic	place[98]	new[98]	_	_
14-30	1989-1996	regions	place[98]	new[98]	_	_
14-31	1997-2000	and	_	_	_	_
14-32	2001-2007	during	_	_	_	_
14-33	2008-2011	the	time[99]	giv[99]	_	_
14-34	2012-2016	time	time[99]	giv[99]	_	_
14-35	2017-2018	.	_	_	_	_

#Text=This notion highlights the need for disease-specific TMB panels and thresholds .
15-1	2019-2023	This	abstract[100]	new[100]	_	_
15-2	2024-2030	notion	abstract[100]	new[100]	_	_
15-3	2031-2041	highlights	_	_	_	_
15-4	2042-2045	the	abstract[101]	new[101]	_	_
15-5	2046-2050	need	abstract[101]	new[101]	_	_
15-6	2051-2054	for	abstract[101]	new[101]	_	_
15-7	2055-2071	disease-specific	abstract[101]|abstract|abstract[104]|abstract[105]	new[101]|new|giv[104]|giv[105]	coref	15-7[105_104]
15-8	2072-2075	TMB	abstract[101]|abstract|abstract[104]|abstract[105]	new[101]|giv|giv[104]|giv[105]	_	_
15-9	2076-2082	panels	abstract[101]|abstract[104]|abstract[105]	new[101]|giv[104]|giv[105]	_	_
15-10	2083-2086	and	abstract[101]|abstract[105]	new[101]|giv[105]	_	_
15-11	2087-2097	thresholds	abstract[101]|abstract[105]|abstract	new[101]|giv[105]|new	_	_
15-12	2098-2099	.	_	_	_	_

#Text=Likewise , the analysis of the MMR status is troubled by the vastity of the existing diagnostic methods in the substantial absence of companion diagnostic ( CD ) tests .
16-1	2100-2108	Likewise	_	_	_	_
16-2	2109-2110	,	_	_	_	_
16-3	2111-2114	the	abstract[107]	giv[107]	coref	23-15[153_107]
16-4	2115-2123	analysis	abstract[107]	giv[107]	_	_
16-5	2124-2126	of	abstract[107]	giv[107]	_	_
16-6	2127-2130	the	abstract[107]|abstract[109]	giv[107]|new[109]	_	_
16-7	2131-2134	MMR	abstract[107]|abstract|abstract[109]	giv[107]|new|new[109]	coref	17-4
16-8	2135-2141	status	abstract[107]|abstract[109]	giv[107]|new[109]	_	_
16-9	2142-2144	is	_	_	_	_
16-10	2145-2153	troubled	_	_	_	_
16-11	2154-2156	by	_	_	_	_
16-12	2157-2160	the	abstract[110]	new[110]	_	_
16-13	2161-2168	vastity	abstract[110]	new[110]	_	_
16-14	2169-2171	of	abstract[110]	new[110]	_	_
16-15	2172-2175	the	abstract[110]|abstract[111]	new[110]|new[111]	coref	22-14[145_111]
16-16	2176-2184	existing	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-17	2185-2195	diagnostic	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-18	2196-2203	methods	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-19	2204-2206	in	abstract[110]|abstract[111]	new[110]|new[111]	_	_
16-20	2207-2210	the	abstract[110]|abstract[111]|abstract[112]	new[110]|new[111]|new[112]	_	_
16-21	2211-2222	substantial	abstract[110]|abstract[111]|abstract[112]	new[110]|new[111]|new[112]	_	_
16-22	2223-2230	absence	abstract[110]|abstract[111]|abstract[112]	new[110]|new[111]|new[112]	_	_
16-23	2231-2233	of	abstract[110]|abstract[111]|abstract[112]	new[110]|new[111]|new[112]	_	_
16-24	2234-2243	companion	abstract[110]|abstract[111]|abstract[112]|person|abstract[115]	new[110]|new[111]|new[112]|new|new[115]	coref	18-23[128_115]
16-25	2244-2254	diagnostic	abstract[110]|abstract[111]|abstract[112]|abstract[115]	new[110]|new[111]|new[112]|new[115]	_	_
16-26	2255-2256	(	abstract[110]|abstract[111]|abstract[112]|abstract[115]	new[110]|new[111]|new[112]|new[115]	_	_
16-27	2257-2259	CD	abstract[110]|abstract[111]|abstract[112]|abstract|abstract[115]	new[110]|new[111]|new[112]|new|new[115]	_	_
16-28	2260-2261	)	abstract[110]|abstract[111]|abstract[112]|abstract[115]	new[110]|new[111]|new[112]|new[115]	_	_
16-29	2262-2267	tests	abstract[110]|abstract[111]|abstract[112]|abstract[115]	new[110]|new[111]|new[112]|new[115]	_	_
16-30	2268-2269	.	_	_	_	_

#Text=In general , MMR IHC is mirrored by microsatellite instability ( MSI ) in endometrial and colorectal cancers .
17-1	2270-2272	In	_	_	_	_
17-2	2273-2280	general	_	_	_	_
17-3	2281-2282	,	_	_	_	_
17-4	2283-2286	MMR	abstract|abstract[117]	giv|giv[117]	coref	23-19[0_117]
17-5	2287-2290	IHC	abstract[117]	giv[117]	_	_
17-6	2291-2293	is	_	_	_	_
17-7	2294-2302	mirrored	_	_	_	_
17-8	2303-2305	by	_	_	_	_
17-9	2306-2320	microsatellite	abstract[118]	new[118]	appos	17-12[0_118]
17-10	2321-2332	instability	abstract[118]	new[118]	_	_
17-11	2333-2334	(	_	_	_	_
17-12	2335-2338	MSI	abstract	giv	coref	18-8
17-13	2339-2340	)	_	_	_	_
17-14	2341-2343	in	_	_	_	_
17-15	2344-2355	endometrial	abstract[120]	new[120]	_	_
17-16	2356-2359	and	abstract[120]	new[120]	_	_
17-17	2360-2370	colorectal	abstract[120]	new[120]	_	_
17-18	2371-2378	cancers	abstract[120]	new[120]	_	_
17-19	2379-2380	.	_	_	_	_

#Text=However , not all MMR-deficient tumors show MSI ( e.g. , breast cancers ) , questioning the interchangeability of these analyses as pan-cancer predictive tests .
18-1	2381-2388	However	_	_	_	_
18-2	2389-2390	,	_	_	_	_
18-3	2391-2394	not	_	_	_	_
18-4	2395-2398	all	object[121]	giv[121]	coref	19-25[136_121]
18-5	2399-2412	MMR-deficient	object[121]	giv[121]	_	_
18-6	2413-2419	tumors	object[121]	giv[121]	_	_
18-7	2420-2424	show	_	_	_	_
18-8	2425-2428	MSI	abstract	giv	appos	18-10[124_0]
18-9	2429-2430	(	_	_	_	_
18-10	2431-2435	e.g.	abstract[124]	giv[124]	_	_
18-11	2436-2437	,	abstract[124]	giv[124]	_	_
18-12	2438-2444	breast	place|abstract[124]	new|giv[124]	_	_
18-13	2445-2452	cancers	abstract[124]	giv[124]	_	_
18-14	2453-2454	)	_	_	_	_
18-15	2455-2456	,	_	_	_	_
18-16	2457-2468	questioning	_	_	_	_
18-17	2469-2472	the	abstract[125]	new[125]	_	_
18-18	2473-2491	interchangeability	abstract[125]	new[125]	_	_
18-19	2492-2494	of	abstract[125]	new[125]	_	_
18-20	2495-2500	these	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-21	2501-2509	analyses	abstract[125]|abstract[126]	new[125]|giv[126]	_	_
18-22	2510-2512	as	abstract[125]	new[125]	_	_
18-23	2513-2523	pan-cancer	abstract[125]|abstract[128]	new[125]|giv[128]	_	_
18-24	2524-2534	predictive	abstract[125]|abstract|abstract[128]	new[125]|new|giv[128]	_	_
18-25	2535-2540	tests	abstract[125]|abstract[128]	new[125]|giv[128]	_	_
18-26	2541-2542	.	_	_	_	_

#Text=Hence , MMR/MSI assays have been originally developed by geneticists to identify Lynch syndrome families and not for choosing the optimal drug to treat acquired tumors .
19-1	2543-2548	Hence	_	_	_	_
19-2	2549-2550	,	_	_	_	_
19-3	2551-2558	MMR/MSI	abstract|abstract[130]	new|giv[130]	_	_
19-4	2559-2565	assays	abstract[130]	giv[130]	_	_
19-5	2566-2570	have	_	_	_	_
19-6	2571-2575	been	_	_	_	_
19-7	2576-2586	originally	_	_	_	_
19-8	2587-2596	developed	_	_	_	_
19-9	2597-2599	by	_	_	_	_
19-10	2600-2611	geneticists	person	new	_	_
19-11	2612-2614	to	_	_	_	_
19-12	2615-2623	identify	_	_	_	_
19-13	2624-2629	Lynch	person|abstract[133]|abstract[134]	new|new[133]|new[134]	_	_
19-14	2630-2638	syndrome	abstract[133]|abstract[134]	new[133]|new[134]	_	_
19-15	2639-2647	families	abstract[134]	new[134]	_	_
19-16	2648-2651	and	_	_	_	_
19-17	2652-2655	not	_	_	_	_
19-18	2656-2659	for	_	_	_	_
19-19	2660-2668	choosing	_	_	_	_
19-20	2669-2672	the	substance[135]	giv[135]	_	_
19-21	2673-2680	optimal	substance[135]	giv[135]	_	_
19-22	2681-2685	drug	substance[135]	giv[135]	_	_
19-23	2686-2688	to	substance[135]	giv[135]	_	_
19-24	2689-2694	treat	substance[135]	giv[135]	_	_
19-25	2695-2703	acquired	substance[135]|object[136]	giv[135]|giv[136]	_	_
19-26	2704-2710	tumors	substance[135]|object[136]	giv[135]|giv[136]	_	_
19-27	2711-2712	.	_	_	_	_

#Text=Given the wide heterogeneity in the repertoire of molecular alterations in immune-related genes across different tumor types (
20-1	2713-2718	Given	_	_	_	_
20-2	2719-2722	the	abstract[137]	new[137]	_	_
20-3	2723-2727	wide	abstract[137]	new[137]	_	_
20-4	2728-2741	heterogeneity	abstract[137]	new[137]	_	_
20-5	2742-2744	in	abstract[137]	new[137]	_	_
20-6	2745-2748	the	abstract[137]|abstract[138]	new[137]|new[138]	coref	32-26[227_138]
20-7	2749-2759	repertoire	abstract[137]|abstract[138]	new[137]|new[138]	_	_
20-8	2760-2762	of	abstract[137]|abstract[138]	new[137]|new[138]	_	_
20-9	2763-2772	molecular	abstract[137]|abstract[138]|abstract[139]	new[137]|new[138]|new[139]	_	_
20-10	2773-2784	alterations	abstract[137]|abstract[138]|abstract[139]	new[137]|new[138]|new[139]	_	_
20-11	2785-2787	in	abstract[137]|abstract[138]|abstract[139]	new[137]|new[138]|new[139]	_	_
20-12	2788-2802	immune-related	abstract[137]|abstract[138]|abstract[139]|abstract[140]	new[137]|new[138]|new[139]|new[140]	_	_
20-13	2803-2808	genes	abstract[137]|abstract[138]|abstract[139]|abstract[140]	new[137]|new[138]|new[139]|new[140]	_	_
20-14	2809-2815	across	abstract[137]|abstract[138]|abstract[139]	new[137]|new[138]|new[139]	_	_
20-15	2816-2825	different	abstract[137]|abstract[138]|abstract[139]|abstract[142]	new[137]|new[138]|new[139]|giv[142]	coref	26-22[178_142]
20-16	2826-2831	tumor	abstract[137]|abstract[138]|abstract[139]|object|abstract[142]	new[137]|new[138]|new[139]|giv|giv[142]	coref	26-23
20-17	2832-2837	types	abstract[137]|abstract[138]|abstract[139]|abstract[142]	new[137]|new[138]|new[139]|giv[142]	_	_
20-18	2838-2839	(	_	_	_	_

#Text=Figure 2
21-1	2840-2846	Figure	abstract[143]	new[143]	_	_
21-2	2847-2848	2	abstract[143]	new[143]	_	_

#Text=) , novel , efficient , reproducible , and reliable techniques coupled with tumor-specific methods and guidelines are needed .
22-1	2849-2850	)	_	_	_	_
22-2	2851-2852	,	_	_	_	_
22-3	2853-2858	novel	_	_	_	_
22-4	2859-2860	,	_	_	_	_
22-5	2861-2870	efficient	_	_	_	_
22-6	2871-2872	,	_	_	_	_
22-7	2873-2885	reproducible	_	_	_	_
22-8	2886-2887	,	_	_	_	_
22-9	2888-2891	and	_	_	_	_
22-10	2892-2900	reliable	_	_	_	_
22-11	2901-2911	techniques	abstract[144]	giv[144]	_	_
22-12	2912-2919	coupled	abstract[144]	giv[144]	_	_
22-13	2920-2924	with	abstract[144]	giv[144]	_	_
22-14	2925-2939	tumor-specific	abstract[144]|abstract[145]|abstract[146]	giv[144]|giv[145]|giv[146]	coref	22-14[146_145]
22-15	2940-2947	methods	abstract[144]|abstract[145]|abstract[146]	giv[144]|giv[145]|giv[146]	_	_
22-16	2948-2951	and	abstract[144]|abstract[146]	giv[144]|giv[146]	_	_
22-17	2952-2962	guidelines	abstract[144]|abstract[146]|abstract	giv[144]|giv[146]|giv	coref	26-13[176_0]
22-18	2963-2966	are	_	_	_	_
22-19	2967-2973	needed	_	_	_	_
22-20	2974-2975	.	_	_	_	_

#Text=Another important issue related to the patient ’s selection for immunotherapy is represented by the PD-L1 analysis by IHC .
23-1	2976-2983	Another	abstract[148]	new[148]	_	_
23-2	2984-2993	important	abstract[148]	new[148]	_	_
23-3	2994-2999	issue	abstract[148]	new[148]	_	_
23-4	3000-3007	related	abstract[148]	new[148]	_	_
23-5	3008-3010	to	abstract[148]	new[148]	_	_
23-6	3011-3014	the	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
23-7	3015-3022	patient	abstract[148]|person[149]|abstract[150]	new[148]|new[149]|giv[150]	_	_
23-8	3023-3025	’s	abstract[148]|person[149]|abstract[150]	new[148]|new[149]|giv[150]	_	_
23-9	3026-3035	selection	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
23-10	3036-3039	for	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
23-11	3040-3053	immunotherapy	abstract[148]|abstract[150]|abstract	new[148]|giv[150]|giv	_	_
23-12	3054-3056	is	_	_	_	_
23-13	3057-3068	represented	_	_	_	_
23-14	3069-3071	by	_	_	_	_
23-15	3072-3075	the	abstract[153]	giv[153]	_	_
23-16	3076-3081	PD-L1	object|abstract[153]	new|giv[153]	coref	24-20
23-17	3082-3090	analysis	abstract[153]	giv[153]	_	_
23-18	3091-3093	by	abstract[153]	giv[153]	_	_
23-19	3094-3097	IHC	abstract[153]|abstract	giv[153]|giv	_	_
23-20	3098-3099	.	_	_	_	_

#Text=In this respect , important harmonization efforts have been made to standardize both the preanalytical and interpretative phases of PD-L1 testing , at least in non-small cell lung cancer ( NSCLC ) .
24-1	3100-3102	In	_	_	_	_
24-2	3103-3107	this	abstract[155]	new[155]	_	_
24-3	3108-3115	respect	abstract[155]	new[155]	_	_
24-4	3116-3117	,	_	_	_	_
24-5	3118-3127	important	abstract[157]	new[157]	_	_
24-6	3128-3141	harmonization	abstract|abstract[157]	new|new[157]	_	_
24-7	3142-3149	efforts	abstract[157]	new[157]	_	_
24-8	3150-3154	have	_	_	_	_
24-9	3155-3159	been	_	_	_	_
24-10	3160-3164	made	_	_	_	_
24-11	3165-3167	to	_	_	_	_
24-12	3168-3179	standardize	_	_	_	_
24-13	3180-3184	both	abstract[158]	new[158]	_	_
24-14	3185-3188	the	abstract[158]	new[158]	_	_
24-15	3189-3202	preanalytical	abstract[158]	new[158]	_	_
24-16	3203-3206	and	abstract[158]	new[158]	_	_
24-17	3207-3221	interpretative	abstract[158]	new[158]	_	_
24-18	3222-3228	phases	abstract[158]	new[158]	_	_
24-19	3229-3231	of	abstract[158]	new[158]	_	_
24-20	3232-3237	PD-L1	abstract[158]|object|abstract[160]	new[158]|giv|new[160]	coref|coref	25-4|25-4[167_160]
24-21	3238-3245	testing	abstract[158]|abstract[160]	new[158]|new[160]	_	_
24-22	3246-3247	,	_	_	_	_
24-23	3248-3250	at	abstract[163]	new[163]	appos	24-31[0_163]
24-24	3251-3256	least	abstract[163]	new[163]	_	_
24-25	3257-3259	in	abstract[163]	new[163]	_	_
24-26	3260-3269	non-small	abstract[163]	new[163]	_	_
24-27	3270-3274	cell	place|abstract[163]	new|new[163]	coref	31-12
24-28	3275-3279	lung	object|abstract[163]	new|new[163]	_	_
24-29	3280-3286	cancer	abstract[163]	new[163]	_	_
24-30	3287-3288	(	_	_	_	_
24-31	3289-3294	NSCLC	abstract	giv	coref	27-14[183_0]
24-32	3295-3296	)	_	_	_	_
24-33	3297-3298	.	_	_	_	_

#Text=The reproducibility of PD-L1 testing in real-life clinical practice evaluated both for “ closed ” and “ open ” platforms , showed overlapping results , particularly when the 22C3 antibody clone was used .
25-1	3299-3302	The	abstract[165]	new[165]	_	_
25-2	3303-3318	reproducibility	abstract[165]	new[165]	_	_
25-3	3319-3321	of	abstract[165]	new[165]	_	_
25-4	3322-3327	PD-L1	abstract[165]|object|abstract[167]	new[165]|giv|giv[167]	_	_
25-5	3328-3335	testing	abstract[165]|abstract[167]	new[165]|giv[167]	_	_
25-6	3336-3338	in	abstract[165]	new[165]	_	_
25-7	3339-3348	real-life	abstract[165]|abstract[168]	new[165]|giv[168]	_	_
25-8	3349-3357	clinical	abstract[165]|abstract[168]	new[165]|giv[168]	_	_
25-9	3358-3366	practice	abstract[165]|abstract[168]	new[165]|giv[168]	_	_
25-10	3367-3376	evaluated	abstract[165]	new[165]	_	_
25-11	3377-3381	both	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-12	3382-3385	for	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-13	3386-3387	“	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-14	3388-3394	closed	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-15	3395-3396	”	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-16	3397-3400	and	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-17	3401-3402	“	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-18	3403-3407	open	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-19	3408-3409	”	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-20	3410-3419	platforms	abstract[165]|abstract[169]	new[165]|new[169]	_	_
25-21	3420-3421	,	_	_	_	_
25-22	3422-3428	showed	_	_	_	_
25-23	3429-3440	overlapping	abstract[170]	new[170]	_	_
25-24	3441-3448	results	abstract[170]	new[170]	_	_
25-25	3449-3450	,	abstract[170]	new[170]	_	_
25-26	3451-3463	particularly	abstract[170]	new[170]	_	_
25-27	3464-3468	when	abstract[170]	new[170]	_	_
25-28	3469-3472	the	abstract[170]|object[173]	new[170]|new[173]	_	_
25-29	3473-3477	22C3	abstract[170]|abstract|object[173]	new[170]|new|new[173]	_	_
25-30	3478-3486	antibody	abstract[170]|substance|object[173]	new[170]|new|new[173]	_	_
25-31	3487-3492	clone	abstract[170]|object[173]	new[170]|new[173]	_	_
25-32	3493-3496	was	abstract[170]	new[170]	_	_
25-33	3497-3501	used	abstract[170]	new[170]	_	_
25-34	3502-3503	.	_	_	_	_

#Text=On the other hand , there are several clues to advise that the same interpretation guidelines should not be translated across different tumor types .
26-1	3504-3506	On	_	_	_	_
26-2	3507-3510	the	_	_	_	_
26-3	3511-3516	other	_	_	_	_
26-4	3517-3521	hand	_	_	_	_
26-5	3522-3523	,	_	_	_	_
26-6	3524-3529	there	_	_	_	_
26-7	3530-3533	are	_	_	_	_
26-8	3534-3541	several	abstract[174]	new[174]	_	_
26-9	3542-3547	clues	abstract[174]	new[174]	_	_
26-10	3548-3550	to	abstract[174]	new[174]	_	_
26-11	3551-3557	advise	abstract[174]	new[174]	_	_
26-12	3558-3562	that	abstract[174]	new[174]	_	_
26-13	3563-3566	the	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
26-14	3567-3571	same	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
26-15	3572-3586	interpretation	abstract[174]|abstract|abstract[176]	new[174]|new|giv[176]	_	_
26-16	3587-3597	guidelines	abstract[174]|abstract[176]	new[174]|giv[176]	_	_
26-17	3598-3604	should	abstract[174]	new[174]	_	_
26-18	3605-3608	not	abstract[174]	new[174]	_	_
26-19	3609-3611	be	abstract[174]	new[174]	_	_
26-20	3612-3622	translated	abstract[174]	new[174]	_	_
26-21	3623-3629	across	_	_	_	_
26-22	3630-3639	different	abstract[178]	giv[178]	_	_
26-23	3640-3645	tumor	object|abstract[178]	giv|giv[178]	coref	27-5
26-24	3646-3651	types	abstract[178]	giv[178]	_	_
26-25	3652-3653	.	_	_	_	_

#Text=For example , the tumor proportion score ( TPS ) works perfectly for lung cancer but not for head and neck cancer , where the combined positive score ( CPS ) is more reliable .
27-1	3654-3657	For	_	_	_	_
27-2	3658-3665	example	_	_	_	_
27-3	3666-3667	,	_	_	_	_
27-4	3668-3671	the	abstract[181]	new[181]	appos	27-9[0_181]
27-5	3672-3677	tumor	object|abstract[180]|abstract[181]	giv|new[180]|new[181]	coref	28-32
27-6	3678-3688	proportion	abstract[180]|abstract[181]	new[180]|new[181]	_	_
27-7	3689-3694	score	abstract[181]	new[181]	_	_
27-8	3695-3696	(	_	_	_	_
27-9	3697-3700	TPS	abstract	giv	coref	27-25[187_0]
27-10	3701-3702	)	_	_	_	_
27-11	3703-3708	works	_	_	_	_
27-12	3709-3718	perfectly	_	_	_	_
27-13	3719-3722	for	_	_	_	_
27-14	3723-3727	lung	abstract[183]	giv[183]	coref	27-19[186_183]
27-15	3728-3734	cancer	abstract[183]	giv[183]	_	_
27-16	3735-3738	but	_	_	_	_
27-17	3739-3742	not	_	_	_	_
27-18	3743-3746	for	_	_	_	_
27-19	3747-3751	head	object|abstract[186]	new|giv[186]	_	_
27-20	3752-3755	and	abstract[186]	giv[186]	_	_
27-21	3756-3760	neck	object|abstract[186]	new|giv[186]	_	_
27-22	3761-3767	cancer	abstract[186]	giv[186]	_	_
27-23	3768-3769	,	abstract[186]	giv[186]	_	_
27-24	3770-3775	where	abstract[186]	giv[186]	_	_
27-25	3776-3779	the	abstract[186]|abstract[187]	giv[186]|giv[187]	appos	27-30[0_187]
27-26	3780-3788	combined	abstract[186]|abstract[187]	giv[186]|giv[187]	_	_
27-27	3789-3797	positive	abstract[186]|abstract[187]	giv[186]|giv[187]	_	_
27-28	3798-3803	score	abstract[186]|abstract[187]	giv[186]|giv[187]	_	_
27-29	3804-3805	(	abstract[186]	giv[186]	_	_
27-30	3806-3809	CPS	abstract[186]|abstract	giv[186]|giv	coref	29-12[206_0]
27-31	3810-3811	)	abstract[186]	giv[186]	_	_
27-32	3812-3814	is	abstract[186]	giv[186]	_	_
27-33	3815-3819	more	abstract[186]	giv[186]	_	_
27-34	3820-3828	reliable	abstract[186]	giv[186]	_	_
27-35	3829-3830	.	_	_	_	_

#Text=These two scoring systems are rather different , given that the former considers only the percentage of PD-L1-positive neoplastic cells , while the latter combines all PD-L1-positive cells ( i.e. , tumor cells , lymphocytes , and macrophages ) into the following formula .
28-1	3831-3836	These	abstract[190]	new[190]	_	_
28-2	3837-3840	two	abstract[190]	new[190]	_	_
28-3	3841-3848	scoring	event|abstract[190]	new|new[190]	_	_
28-4	3849-3856	systems	abstract[190]	new[190]	_	_
28-5	3857-3860	are	_	_	_	_
28-6	3861-3867	rather	_	_	_	_
28-7	3868-3877	different	_	_	_	_
28-8	3878-3879	,	_	_	_	_
28-9	3880-3885	given	_	_	_	_
28-10	3886-3890	that	_	_	_	_
28-11	3891-3894	the	_	_	_	_
28-12	3895-3901	former	_	_	_	_
28-13	3902-3911	considers	_	_	_	_
28-14	3912-3916	only	abstract[191]	new[191]	_	_
28-15	3917-3920	the	abstract[191]	new[191]	_	_
28-16	3921-3931	percentage	abstract[191]	new[191]	_	_
28-17	3932-3934	of	abstract[191]	new[191]	_	_
28-18	3935-3949	PD-L1-positive	abstract[191]|substance|animal[193]	new[191]|new|new[193]	coref|coref	28-27|28-26[196_193]
28-19	3950-3960	neoplastic	abstract[191]|animal[193]	new[191]|new[193]	_	_
28-20	3961-3966	cells	abstract[191]|animal[193]	new[191]|new[193]	_	_
28-21	3967-3968	,	_	_	_	_
28-22	3969-3974	while	_	_	_	_
28-23	3975-3978	the	abstract[194]	new[194]	_	_
28-24	3979-3985	latter	abstract[194]	new[194]	_	_
28-25	3986-3994	combines	_	_	_	_
28-26	3995-3998	all	animal[196]	giv[196]	appos	28-30[198_196]
28-27	3999-4013	PD-L1-positive	substance|animal[196]	giv|giv[196]	_	_
28-28	4014-4019	cells	animal[196]	giv[196]	_	_
28-29	4020-4021	(	_	_	_	_
28-30	4022-4026	i.e.	animal[198]|animal[199]	giv[198]|giv[199]	appos|appos	28-30[199_198]|28-35[0_199]
28-31	4027-4028	,	animal[198]|animal[199]	giv[198]|giv[199]	_	_
28-32	4029-4034	tumor	object|animal[198]|animal[199]	giv|giv[198]|giv[199]	coref	31-21
28-33	4035-4040	cells	animal[198]|animal[199]	giv[198]|giv[199]	_	_
28-34	4041-4042	,	animal[199]	giv[199]	_	_
28-35	4043-4054	lymphocytes	animal[199]|animal	giv[199]|giv	appos	28-38
28-36	4055-4056	,	animal[199]	giv[199]	_	_
28-37	4057-4060	and	animal[199]	giv[199]	_	_
28-38	4061-4072	macrophages	animal[199]|animal	giv[199]|giv	coref	32-13[224_0]
28-39	4073-4074	)	_	_	_	_
28-40	4075-4079	into	_	_	_	_
28-41	4080-4083	the	abstract[202]	new[202]	_	_
28-42	4084-4093	following	abstract[202]	new[202]	_	_
28-43	4094-4101	formula	abstract[202]	new[202]	_	_
28-44	4102-4103	.	_	_	_	_

#Text=Although the CPS can theoretically exceed the value of 100 , the maximum score is defined as 100 .
29-1	4104-4112	Although	_	_	_	_
29-2	4113-4116	the	abstract[203]	new[203]	_	_
29-3	4117-4120	CPS	abstract[203]	new[203]	_	_
29-4	4121-4124	can	_	_	_	_
29-5	4125-4138	theoretically	_	_	_	_
29-6	4139-4145	exceed	_	_	_	_
29-7	4146-4149	the	abstract[204]	giv[204]	_	_
29-8	4150-4155	value	abstract[204]	giv[204]	_	_
29-9	4156-4158	of	abstract[204]	giv[204]	_	_
29-10	4159-4162	100	abstract[204]|abstract	giv[204]|new	coref	29-18
29-11	4163-4164	,	_	_	_	_
29-12	4165-4168	the	abstract[206]	giv[206]	_	_
29-13	4169-4176	maximum	abstract[206]	giv[206]	_	_
29-14	4177-4182	score	abstract[206]	giv[206]	_	_
29-15	4183-4185	is	_	_	_	_
29-16	4186-4193	defined	_	_	_	_
29-17	4194-4196	as	_	_	_	_
29-18	4197-4200	100	abstract	giv	_	_
29-19	4201-4202	.	_	_	_	_

#Text=Fascinating perspectives are being provided by experimental models addressing the plasticity of the cellular inflammatory response of the host .
30-1	4203-4214	Fascinating	abstract[208]	new[208]	_	_
30-2	4215-4227	perspectives	abstract[208]	new[208]	_	_
30-3	4228-4231	are	_	_	_	_
30-4	4232-4237	being	_	_	_	_
30-5	4238-4246	provided	_	_	_	_
30-6	4247-4249	by	_	_	_	_
30-7	4250-4262	experimental	abstract[209]	new[209]	_	_
30-8	4263-4269	models	abstract[209]	new[209]	_	_
30-9	4270-4280	addressing	abstract[209]	new[209]	_	_
30-10	4281-4284	the	abstract[209]|abstract[210]	new[209]|new[210]	_	_
30-11	4285-4295	plasticity	abstract[209]|abstract[210]	new[209]|new[210]	_	_
30-12	4296-4298	of	abstract[209]|abstract[210]	new[209]|new[210]	_	_
30-13	4299-4302	the	abstract[209]|abstract[210]|abstract[211]	new[209]|new[210]|giv[211]	_	_
30-14	4303-4311	cellular	abstract[209]|abstract[210]|abstract[211]	new[209]|new[210]|giv[211]	_	_
30-15	4312-4324	inflammatory	abstract[209]|abstract[210]|abstract[211]	new[209]|new[210]|giv[211]	_	_
30-16	4325-4333	response	abstract[209]|abstract[210]|abstract[211]	new[209]|new[210]|giv[211]	_	_
30-17	4334-4336	of	abstract[209]|abstract[210]|abstract[211]	new[209]|new[210]|giv[211]	_	_
30-18	4337-4340	the	abstract[209]|abstract[210]|abstract[211]|animal[212]	new[209]|new[210]|giv[211]|new[212]	_	_
30-19	4341-4345	host	abstract[209]|abstract[210]|abstract[211]|animal[212]	new[209]|new[210]|giv[211]|new[212]	_	_
30-20	4346-4347	.	_	_	_	_

#Text=There are several lines of evidence to suggest that the myeloid-derived cell function is a finely tuned mechanism to control tumor growth .
31-1	4348-4353	There	_	_	_	_
31-2	4354-4357	are	_	_	_	_
31-3	4358-4365	several	abstract[213]	new[213]	_	_
31-4	4366-4371	lines	abstract[213]	new[213]	_	_
31-5	4372-4374	of	abstract[213]	new[213]	_	_
31-6	4375-4383	evidence	abstract[213]|abstract[214]	new[213]|new[214]	_	_
31-7	4384-4386	to	abstract[213]|abstract[214]	new[213]|new[214]	_	_
31-8	4387-4394	suggest	abstract[213]|abstract[214]	new[213]|new[214]	_	_
31-9	4395-4399	that	abstract[213]|abstract[214]	new[213]|new[214]	_	_
31-10	4400-4403	the	abstract[213]|abstract[214]|abstract[216]	new[213]|new[214]|new[216]	coref	31-15[217_216]
31-11	4404-4419	myeloid-derived	abstract[213]|abstract[214]|abstract[216]	new[213]|new[214]|new[216]	_	_
31-12	4420-4424	cell	abstract[213]|abstract[214]|place|abstract[216]	new[213]|new[214]|giv|new[216]	_	_
31-13	4425-4433	function	abstract[213]|abstract[214]|abstract[216]	new[213]|new[214]|new[216]	_	_
31-14	4434-4436	is	abstract[213]|abstract[214]	new[213]|new[214]	_	_
31-15	4437-4438	a	abstract[213]|abstract[214]|abstract[217]	new[213]|new[214]|giv[217]	ana	32-10[0_217]
31-16	4439-4445	finely	abstract[213]|abstract[214]|abstract[217]	new[213]|new[214]|giv[217]	_	_
31-17	4446-4451	tuned	abstract[213]|abstract[214]|abstract[217]	new[213]|new[214]|giv[217]	_	_
31-18	4452-4461	mechanism	abstract[213]|abstract[214]|abstract[217]	new[213]|new[214]|giv[217]	_	_
31-19	4462-4464	to	abstract[213]|abstract[214]|abstract[217]	new[213]|new[214]|giv[217]	_	_
31-20	4465-4472	control	abstract[213]|abstract[214]|abstract[217]	new[213]|new[214]|giv[217]	_	_
31-21	4473-4478	tumor	abstract[213]|abstract[214]|abstract[217]|object|event[219]	new[213]|new[214]|giv[217]|giv|new[219]	coref	32-14
31-22	4479-4485	growth	abstract[213]|abstract[214]|abstract[217]|event[219]	new[213]|new[214]|giv[217]|new[219]	_	_
31-23	4486-4487	.	_	_	_	_

#Text=Specifically , both in local and hematopoietic niches , its crosstalk with the tumor cells as well as with exogenous stimuli , is based on the microbiota repertoire .
32-1	4488-4500	Specifically	_	_	_	_
32-2	4501-4502	,	_	_	_	_
32-3	4503-4507	both	place[220]	new[220]	_	_
32-4	4508-4510	in	place[220]	new[220]	_	_
32-5	4511-4516	local	place[220]	new[220]	_	_
32-6	4517-4520	and	place[220]	new[220]	_	_
32-7	4521-4534	hematopoietic	place[220]	new[220]	_	_
32-8	4535-4541	niches	place[220]	new[220]	_	_
32-9	4542-4543	,	_	_	_	_
32-10	4544-4547	its	abstract|abstract[222]	giv|new[222]	_	_
32-11	4548-4557	crosstalk	abstract[222]	new[222]	_	_
32-12	4558-4562	with	abstract[222]	new[222]	_	_
32-13	4563-4566	the	abstract[222]|animal[224]	new[222]|giv[224]	_	_
32-14	4567-4572	tumor	abstract[222]|object|animal[224]	new[222]|giv|giv[224]	_	_
32-15	4573-4578	cells	abstract[222]|animal[224]	new[222]|giv[224]	_	_
32-16	4579-4581	as	_	_	_	_
32-17	4582-4586	well	_	_	_	_
32-18	4587-4589	as	_	_	_	_
32-19	4590-4594	with	_	_	_	_
32-20	4595-4604	exogenous	abstract[225]	new[225]	_	_
32-21	4605-4612	stimuli	abstract[225]	new[225]	_	_
32-22	4613-4614	,	_	_	_	_
32-23	4615-4617	is	_	_	_	_
32-24	4618-4623	based	_	_	_	_
32-25	4624-4626	on	_	_	_	_
32-26	4627-4630	the	abstract[227]	giv[227]	_	_
32-27	4631-4641	microbiota	person|abstract[227]	new|giv[227]	_	_
32-28	4642-4652	repertoire	abstract[227]	giv[227]	_	_
32-29	4653-4654	.	_	_	_	_
